Menu
GeneBe

CEBPE

CCAAT enhancer binding protein epsilon, the group of CCAAT/enhancer binding proteins |Basic leucine zipper proteins

Basic information

Region (hg38): 14:23117035-23120256

Links

ENSG00000092067NCBI:1053OMIM:600749HGNC:1836Uniprot:Q15744AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • specific granule deficiency (Supportive), mode of inheritance: AR
  • specific granule deficiency 1 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Specific granule deficiency 1; Immunodeficiency 108 with autoinflammationARAllergy/Immunology/InfectiousIndividuals with Specific granule deficiency have severe immunocompromise, and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; Immunodeficiency108 with autoinflammation involves immunodeficiency, and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficiaAllergy/Immunology/Infectious10359588; 11313242; 31201888

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CEBPE gene.

  • Specific granule deficiency (150 variants)
  • Inborn genetic diseases (11 variants)
  • not provided (9 variants)
  • Specific granule deficiency 1 (3 variants)
  • CEBPE-related condition (2 variants)
  • SPECIFIC GRANULE DEFICIENCY 1, AUTOSOMAL DOMINANT (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CEBPE gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
50
clinvar
4
clinvar
56
missense
1
clinvar
89
clinvar
2
clinvar
92
nonsense
1
clinvar
1
clinvar
2
start loss
0
frameshift
2
clinvar
1
clinvar
3
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
0
splice region
1
1
non coding
3
clinvar
2
clinvar
5
Total 3 2 93 55 6

Variants in CEBPE

This is a list of pathogenic ClinVar variants found in the CEBPE region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
14-23117491-C-T Specific granule deficiency • Specific granule deficiency 1 • CEBPE-related disorder Conflicting classifications of pathogenicity (Jan 29, 2024)714668
14-23117500-C-T Inborn genetic diseases Uncertain significance (Dec 13, 2021)2266600
14-23117504-C-T Uncertain significance (Oct 01, 2021)2439893
14-23117505-G-A Specific granule deficiency • CEBPE-related disorder Likely benign (Feb 29, 2024)787006
14-23117513-T-C Specific granule deficiency Uncertain significance (Aug 03, 2020)1007479
14-23117520-G-A Specific granule deficiency Likely benign (Oct 17, 2022)1143437
14-23117523-C-T Specific granule deficiency Likely benign (Nov 07, 2022)1139583
14-23117529-A-G Specific granule deficiency Likely benign (Jun 20, 2022)1647269
14-23117535-C-T Specific granule deficiency Likely benign (Apr 10, 2023)3020916
14-23117538-G-C Specific granule deficiency Likely benign (Oct 02, 2021)1531344
14-23117539-C-T Specific granule deficiency Uncertain significance (Aug 19, 2022)1015584
14-23117540-G-A Inborn genetic diseases Uncertain significance (Aug 22, 2023)2621113
14-23117543-A-C Inborn genetic diseases Uncertain significance (Jan 08, 2024)3141870
14-23117544-G-C Specific granule deficiency Likely benign (May 04, 2019)795218
14-23117554-A-C Specific granule deficiency Uncertain significance (Apr 06, 2022)2122124
14-23117555-G-A Specific granule deficiency Uncertain significance (Aug 01, 2022)855048
14-23117561-C-T Specific granule deficiency Uncertain significance (Dec 14, 2023)2895439
14-23117585-CGCGGCT-C Specific granule deficiency 1 Pathogenic (Sep 15, 2022)1705852
14-23117586-G-A Specific granule deficiency • CEBPE-related disorder Benign (Jan 31, 2024)461468
14-23117591-T-G Inborn genetic diseases Uncertain significance (Nov 30, 2022)2329723
14-23117593-C-T Specific granule deficiency Uncertain significance (Jun 13, 2022)1363073
14-23117600-G-A Specific granule deficiency Uncertain significance (Jun 09, 2022)1956268
14-23117604-G-A Specific granule deficiency Likely benign (Aug 10, 2022)1654505
14-23117610-T-C Specific granule deficiency Likely benign (Feb 19, 2022)1980478
14-23117612-C-T Specific granule deficiency Uncertain significance (Jul 12, 2022)1405865

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CEBPEprotein_codingprotein_codingENST00000206513 22313
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.007080.9271257260161257420.0000636
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.2331801890.9520.00001311788
Missense in Polyphen8487.3330.96184858
Synonymous-0.7059081.91.100.00000577609
Loss of Function1.59510.60.4738.07e-797

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00009050.0000904
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.00004660.0000462
European (Non-Finnish)0.00007280.0000703
Middle Eastern0.00005440.0000544
South Asian0.00009880.0000980
Other0.0001660.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcriptional activator (PubMed:26019275). C/EBP are DNA-binding proteins that recognize two different motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers. Required for the promyelocyte- myelocyte transition in myeloid differentiation (PubMed:10359588). {ECO:0000269|PubMed:10359588, ECO:0000269|PubMed:26019275}.;
Disease
DISEASE: Specific granule deficiency 1 (SGD1) [MIM:245480]: An autosomal recessive disorder characterized by recurrent pyogenic infections, defective neutrophil chemotaxis and bactericidal activity, and lack of neutrophil secondary granule proteins. Neutrophils of affected individuals lack lactoferrin and show abnormal nuclear segmentation, bilobed nuclei, low alkaline phosphatase, and increased number of neutrophil mitochondria and ribosomes. {ECO:0000269|PubMed:10359588, ECO:0000269|PubMed:11313242, ECO:0000269|PubMed:26019275}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Acute myeloid leukemia - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human) (Consensus)

Recessive Scores

pRec
0.213

Intolerance Scores

loftool
0.507
rvis_EVS
-0.38
rvis_percentile_EVS
27.69

Haploinsufficiency Scores

pHI
0.483
hipred
N
hipred_score
0.339
ghis
0.520

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
E
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.944

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Cebpe
Phenotype
cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); respiratory system phenotype; immune system phenotype; skeleton phenotype; digestive/alimentary phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype;

Gene ontology

Biological process
phagocytosis;defense response;macrophage differentiation;granulocyte differentiation;cytokine biosynthetic process;defense response to bacterium;positive regulation of transcription by RNA polymerase II;cellular response to lipopolysaccharide
Cellular component
nucleus;nucleoplasm
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;protein binding;protein homodimerization activity;protein heterodimerization activity